# Rosiglitazone

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/rosiglitazone
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-28
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** RSG, TZD, Glitazone, PPARγ agonist, Thiazolidinedione, Avandia, Insulin sensitizer

## Overview

Rosiglitazone is a thiazolidinedione class drug that functions as a selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, improving [insulin sensitivity](/ingredients/condition/weight-management) in peripheral tissues. It reduces blood glucose in type 2 diabetes patients by enhancing glucose transporter (GLUT4) expression and reducing hepatic glucose output.

## Health Benefits

• Improves [insulin sensitivity](/ingredients/condition/weight-management) by acting as a PPARγ agonist, enhancing glucose uptake in cells. [4]
• Developed specifically for managing type 2 diabetes, helping to regulate blood sugar levels. [1][2]
• Provides a potential option for patients needing insulin sensitization. [2]
• Targets molecular pathways involved in glucose and lipid metabolism. [1]
• Aids in the reduction of blood glucose levels through its unique mechanism of action. [4]

## Mechanism of Action

Rosiglitazone binds selectively to peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear transcription factor highly expressed in adipose tissue, skeletal muscle, and liver. This binding upregulates genes encoding GLUT4 glucose transporters and adiponectin, while downregulating resistin and free fatty acid release, collectively enhancing peripheral [insulin sensitivity](/ingredients/condition/weight-management). Additionally, PPARγ activation reduces hepatic gluconeogenesis by suppressing phosphoenolpyruvate carboxykinase (PEPCK) gene expression, lowering fasting plasma glucose concentrations.

## Clinical Summary

Randomized controlled trials involving thousands of patients demonstrated that rosiglitazone (4–8 mg/day) reduced HbA1c by approximately 0.8–1.5 percentage points compared to placebo over 26–52 weeks. The landmark ADOPT trial (n=4,360) showed rosiglitazone provided superior glycemic durability over metformin and glyburide over five years, though with greater weight gain and edema. The controversial RECORD trial (n=4,447) and a 2007 meta-analysis by Nissen et al. raised concerns about a ~43% increased relative risk of myocardial infarction, leading to significant regulatory restrictions. Evidence for glycemic efficacy is robust, but [cardiovascular](/ingredients/condition/heart-health) safety concerns substantially limit its clinical use today.

## Nutritional Profile

Rosiglitazone is a synthetic pharmaceutical compound (thiazolidinedione class), not a nutritional ingredient, and therefore has no macronutrient, micronutrient, vitamin, mineral, or fiber content. It is not consumed as a food or supplement for nutritional value. Key chemical identity: molecular formula C18H19N3O3S, molecular weight 357.43 g/mol. The active moiety is a thiazolidinedione ring system linked to a pyridyl-ethylamino-methylphenyl chain. Available pharmaceutical formulations include oral tablets (Avandia) at doses of 2 mg, 4 mg, and 8 mg per tablet, containing inactive excipients such as hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide. Bioavailability: approximately 99% absorbed after oral administration, peak plasma concentration reached in approximately 1 hour, protein binding ~99.8% (primarily albumin), hepatic [metabolism](/ingredients/condition/weight-management) via CYP2C8 (major) and CYP2C9 (minor), half-life 3–4 hours. No caloric contribution, no glycemic index, and no dietary nutrient value. Its biological activity is entirely pharmacological, acting as a PPARγ agonist at nanomolar concentrations rather than through any nutritional mechanism.

## Dosage & Preparation

No clinically studied dosage ranges for forms like extract, powder, or standardized extracts are detailed. Rosiglitazone is typically formulated as maleate salt tablets (e.g., Avandia). Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Rosiglitazone carries an FDA black box warning for congestive heart failure risk due to fluid retention and plasma volume expansion, and is contraindicated in patients with NYHA Class III–IV heart failure. A significant [cardiovascular](/ingredients/condition/heart-health) safety concern exists regarding increased myocardial infarction risk, and the FDA restricted its use from 2010–2013, later partially lifting restrictions after further review. Drug interactions include potentiation of hypoglycemia when combined with insulin or sulfonylureas, and CYP2C8 inhibitors such as gemfibrozil can increase rosiglitazone plasma levels by up to 2-fold. Rosiglitazone is classified as FDA Pregnancy Category C and is not recommended during pregnancy or breastfeeding.

## Scientific Research

The research dossier lacks specific details on human clinical trials, RCTs, or meta-analyses, as no PMIDs or study outcomes are provided. Rosiglitazone is noted as an antidiabetic agent, but detailed trial data is not available.

## Historical & Cultural Context

Rosiglitazone has no historical or traditional use, as it is a modern synthetic pharmaceutical. It does not have roots in traditional herbal practices such as Ayurveda or Traditional Chinese Medicine.

## Synergistic Combinations

Metformin, Pioglitazone, Insulin, Sulfonylureas, DPP-4 inhibitors

## Frequently Asked Questions

### How does rosiglitazone lower blood sugar?

Rosiglitazone lowers blood sugar by activating PPARγ receptors in fat, muscle, and liver cells, which increases GLUT4 glucose transporter expression and adiponectin secretion. This makes cells significantly more responsive to insulin, reducing fasting plasma glucose and post-meal blood sugar spikes. It also suppresses PEPCK enzyme activity in the liver, cutting excess glucose production between meals.

### What is the standard rosiglitazone dosage for type 2 diabetes?

The standard starting dose of rosiglitazone is 4 mg per day, taken as a single dose or divided into two 2 mg doses. If glycemic response is inadequate after 8–12 weeks, the dose may be increased to a maximum of 8 mg per day. Dose adjustments are not required for renal impairment, but hepatic function should be monitored as rosiglitazone is metabolized primarily by CYP2C8 in the liver.

### Is rosiglitazone still available and why was it restricted?

Rosiglitazone (brand name Avandia) remains available in the United States but under restricted use through the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, which was partially relaxed in 2013. The original 2010 restrictions followed a meta-analysis suggesting a ~43% increased relative risk of myocardial infarction, alarming regulators and clinicians. Prescribers must document that patients have been informed of cardiovascular risks and that alternative therapies are inadequate before prescribing.

### What are the most common side effects of rosiglitazone?

The most common side effects include fluid retention leading to edema (reported in 4–8% of patients), weight gain averaging 2–4 kg over 26 weeks, and upper respiratory tract infections. More serious risks include exacerbation of congestive heart failure, bone fractures (particularly in women, affecting distal limbs), and the debated increased risk of myocardial infarction. Liver enzyme elevations (ALT) can occur, though severe hepatotoxicity is rare; liver function tests are recommended periodically.

### How does rosiglitazone compare to metformin for type 2 diabetes?

The ADOPT trial directly compared rosiglitazone, metformin, and glyburide over five years in drug-naive type 2 diabetes patients (n=4,360), finding rosiglitazone provided the most durable glycemic control with the lowest rate of monotherapy failure. However, metformin is strongly preferred as first-line therapy due to its established cardiovascular safety profile, weight neutrality or modest weight loss, and lower cost, whereas rosiglitazone carries cardiovascular concerns and causes weight gain. Current clinical guidelines from the ADA recommend metformin as the preferred initial agent, reserving rosiglitazone for specific situations where alternatives are inadequate.

### Does rosiglitazone interact with other diabetes medications?

Rosiglitazone can be used alongside other diabetes medications like metformin or sulfonylureas, but this combination may increase the risk of hypoglycemia and fluid retention. It is important to inform your healthcare provider about all medications you are taking, as rosiglitazone may interact with certain drugs that affect liver function or glucose metabolism. Dose adjustments may be necessary when combining rosiglitazone with other antidiabetic agents to maintain safety and efficacy.

### Who should avoid taking rosiglitazone due to safety concerns?

Rosiglitazone should be avoided by patients with a history of heart failure, myocardial infarction, or severe cardiovascular disease, as it has been associated with increased fluid retention and potential cardiac risks. Individuals with active liver disease or significantly elevated liver enzymes should not use rosiglitazone without close medical supervision. Pregnant women should avoid rosiglitazone as its safety in pregnancy has not been established, and breastfeeding while taking this medication is not recommended.

### What does clinical research show about rosiglitazone's effectiveness compared to other insulin sensitizers?

Clinical trials demonstrate that rosiglitazone effectively improves insulin sensitivity and reduces blood glucose levels in type 2 diabetes patients, with effects comparable to or sometimes superior to other thiazolidinediones like pioglitazone in certain studies. However, concerns about cardiovascular safety identified in post-market surveillance have made regulatory agencies restrict its use, and many newer insulin-sensitizing agents with potentially more favorable safety profiles have since been developed. Current research emphasizes that while rosiglitazone's glucose-lowering efficacy is well-established, the risk-benefit ratio must be carefully evaluated for individual patients in consultation with their physicians.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*